CLINICAL TRIALS PROFILE FOR QUETIAPINE FUMARATE
✉ Email this page to a colleague
All Clinical Trials for QUETIAPINE FUMARATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034775 ↗ | A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2001-08-01 | The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia. |
| NCT00060489 ↗ | Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression | Completed | AstraZeneca | Phase 3 | 2002-09-01 | The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder. |
| NCT00081380 ↗ | Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder | Completed | AstraZeneca | Phase 3 | 2004-03-01 | The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA. |
| NCT00083954 ↗ | Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression | Completed | AstraZeneca | Phase 3 | 2004-06-01 | The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks. |
| NCT00085891 ↗ | Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia | Completed | AstraZeneca | Phase 3 | 2004-06-01 | The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks. |
| NCT00090311 ↗ | Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania | Completed | AstraZeneca | Phase 3 | 2004-07-01 | The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania. |
| NCT00090324 ↗ | Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia | Completed | AstraZeneca | Phase 3 | 2004-09-01 | The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for QUETIAPINE FUMARATE
Condition Name
Clinical Trial Locations for QUETIAPINE FUMARATE
Trials by Country
Clinical Trial Progress for QUETIAPINE FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for QUETIAPINE FUMARATE
Sponsor Name
